Current Edition Of Indian Pharmacopoeia [hot]

By 2026, the IPC aims to have 80% of its monographs harmonized with the USP and Ph. Eur., making India’s domestic standard virtually identical to global benchmarks.

There is a strengthened focus on essential medicines, specifically anti-tubercular (Anti-TB) , anti-diabetic , and anti-cancer drugs.

The IP 2022 has expanded its repository significantly. It includes a total of . In this edition, a substantial number of new monographs were added, covering: current edition of indian pharmacopoeia

In the complex and critical world of pharmaceuticals, the bridge between a chemical synthesis and a life-saving medicine is built upon standards. For India, often hailed as the "Pharmacy of the World," the bedrock of these standards is the Indian Pharmacopoeia (IP).

In response to the global AMR crisis, IP 2022 introduced stricter limits on related substances in antibiotics like ceftriaxone, azithromycin, and levofloxacin. The current edition mandates testing for certain parenteral antibiotics. By 2026, the IPC aims to have 80%

Given the global focus on immunization, particularly in the wake of the COVID-19 pandemic, the IP 2022 placed a heavy emphasis on biological standards. It includes updated monographs for vaccines, sera, and recombinant products. The standards for viral vaccines and monoclonal antibodies have been made more stringent to align with World Health Organization (WHO) pre-qualification requirements.

Before delving into the specifics of the current edition, it is essential to understand the document's role. The Indian Pharmacopoeia is an officially recognized book of standards for drugs published by the Indian Pharmacopoeia Commission (IPC) on behalf of the Ministry of Health and Family Welfare, Government of India. The IP 2022 has expanded its repository significantly

IP 2022 encourages the use of modern instrumentation, including: